Showing 6791-6800 of 9883 results for "".
- New Case Study Highlights Black Henna Tattoo Riskshttps://practicaldermatology.com/news/new-case-study-highlights-black-henna-tattoo-risks/2458573/Black henna tattoos should be avoided, especially during foreign travel, UK doctors warn in BMJ Case Reports. Researchers from the University of Sheffiel
- Global Derm Market Set to Soar Through 2022https://practicaldermatology.com/news/global-derm-market-set-to-soar-through-2022/2458579/The global dermatology market is set to boom from $20 billion in 2015 to $33.7 billion by 2022, representing a compound annual growth rate of 7.7%,
- Sienna Biopharmaceuticals Completes $34 Million Series A Financinghttps://practicaldermatology.com/news/sienna-biopharmaceuticals-completes-34-million-series-a-financing/2458586/Sienna Biopharmaceuticals, Inc., a development stage company focused on aesthetics and medical dermatology, completed a $34 million Series A financing led by ARCH Venture Partners. Additional investors included Altitude Life Science Ventures, Partner Fund Management, and Venvest Capital, as well
- Vitiligo and Gray Hair Treatment Breakthrough? Study IDs Mechanism That Controls Skin and Hair Colorhttps://practicaldermatology.com/news/vitiligo-and-gray-hair-treatment-breakthrough-study-ids-mechanism-that-controls-skin-and-hair-color/2458587/A pair of molecular signals controls skin and hair color in mice and humans - and could be targeted by new drugs to treat skin pigment disorders like vitiligo, according to a report out of NYU Langone Medical Center in New York City. Finding ways to activate these pathways could lea
- BioPharmX Reports Full Patient Enrollment in Phase 2a Study of BPX-01https://practicaldermatology.com/news/biopharmx-reports-full-patient-enrollment-in-phase-2a-study-of-bpx-01/2458592/BioPharmX Corporation has completed enrollment for its Phase 2a study of the novel topical minocycline gel BPX-01. The Phase 2a study will assess the safety of BPX-01 in 30 patients randomized to 30 days of treatment with either BPX-01 or a placebo. The endpoints of this study include red
- Study: Viveve® Improves Vaginal Laxityhttps://practicaldermatology.com/news/study-viveve-improves-vaginal-laxity/2458595/The Viveve System improves vaginal laxity when compared with a sham procedure, a new study suggests. Top-line results from the VIveve Treatment of the Vaginal Introitus to EValuate Efficacy (VIVEVE 1) show that the procedure is both safe and effec
- SCCA Doctors Address the Future of Immunotherapy for Melanomahttps://practicaldermatology.com/news/scca-doctors-address-the-future-of-immunotherapy-for-melanoma/2458600/Immunotherapy is the hottest topic in cancer care today, and metastatic melanoma is among the first type to benefit from this fourth cancer therapy. Two Seattle Cancer Care Alliance (SCC
- CeraVe® Named Official Skincare Sponsor of LPGA Golf Clinics for Womenhttps://practicaldermatology.com/news/cerave-named-official-skincare-sponsor-of-lpga-golf-clinics-for-women/2458599/CeraVe® skincare products, thave been named Official Skincare Partner of the Ladies Professional Golf Association (LPGA) Golf Clinics for Women, reports Valeant <
- Checkpoint Inhibitor Shows Promise in MCChttps://practicaldermatology.com/news/checkpoint-inhibitor-shows-promise-in-mcc/2458603/Advanced Merkel cell carcinoma patients who received KEYTRUDA® (pembrolizumab) showed more durable responses than what is typically seen with standard chemotherapy, according to a study presented at the American Association for Cancer Research Annual Meeting 2016 in New Orleans and simul
- GMC, RCS Raise the Bar for Cosmetic Surgery in the UKhttps://practicaldermatology.com/news/gmc-rcs-raise-the-bar-for-cosmetic-surgery-in-the-uk/2458611/Starting in June 2016, the UK will have new rules and regulations governing the practice of cosmetic surgery and the practices of cosmetic surgeons. The new guidance, issued by the General Medical Council (GMC), aims to reign in cosmetic cowboys in the